BB Biotech AG (XSWX:BION) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


XSWX:BION BB Biotech AG XSWX:BION
33 GF Score
Price CHF47.60
! 4 Warning Signs
View Full Analysis

What is BB Biotech AG LT-Debt-to-Total-Asset?

BB Biotech AG XSWX:BION -0.42% 33 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BB Biotech AG's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

BB Biotech AG's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

BB Biotech AG  (XSWX:BION) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BB Biotech AG LT-Debt-to-Total-Asset Related Terms

BB Biotech AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG LT-Debt-to-Total-Asset Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.12 0.12 0.05 0.00

BB Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:BION
33GF Score
BB Biotech AG XSWX:BION
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG LT-Debt-to-Total-Asset Calculation

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/2785.759
=0.00

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/2641.182
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
BB Biotech AG (XSWX:BION) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BB Biotech AG and its competitors.
Is BB Biotech AG's LT-Debt-to-Total-Asset too high?
BB Biotech AG's current LT-Debt-to-Total-Asset is 0.00. Overall, BB Biotech AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's LT-Debt-to-Total-Asset compare to VRTX and REGN?
BB Biotech AG's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. BB Biotech AG's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
33GF Score

Get the complete analysis for XSWX:BION

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF47.60
Price